Over-the-counter budesonide-formoterol for asthma can save lives and money

Published Date: 08 Mar 2023

A computerized study examined the use of budesonide-formoterol as needed versus inhaled epinephrine for the management of asthma.

Read Full News

Latest News

Two Symptoms Linked to Antibiotic Delays in Presumed Sepsis

— GI and respiratory symptoms at presentation both flagged in observational study

Exercise and Cancer Survival; COVID Vaccine and Immune Checkpoint Inhibitors

— Also in TTHealthWatch: colonoscopy after polyp removal

BPAP Intervention Flops in Asthma Study

Goal of decreasing the duration of beta-agonist therapy in the ED showed no significant effect

To Face Scrutiny at ESC: Statins for the Elderly, New Heart Attack Therapies

STAREE trial will give its verdict on primary prevention statins in people ages 70 and up

Radio Silence on Mitch McConnell's Health Persists

84-year-old senator hasn't been seen in public since his hospitalization nearly 3 months ago

Cefepime Tied to Higher Mortality Odds vs Other Beta-Lactams

The danger may be in the dosing, not in the drug itself

Todays Updates

Baseline RV Dysfunction May predict Sotatercept response in PAH

Baseline RV Dysfunction May predict Sotatercept response in PAH

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

Todays Updates

Baseline RV Dysfunction May predict Sotatercept response in PAH

Baseline RV Dysfunction May predict Sotatercept response in PAH

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

Latest News

— GI and respiratory symptoms at presentation both flagged in observational study

— Also in TTHealthWatch: colonoscopy after polyp removal

Goal of decreasing the duration of beta-agonist therapy in the ED showed no significant effect

STAREE trial will give its verdict on primary prevention statins in people ages 70 and up

84-year-old senator hasn't been seen in public since his hospitalization nearly 3 months ago

The danger may be in the dosing, not in the drug itself

News All Time

Discordant Tissue Findings in Suspected HLH

Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome characterized by an exaggerated immune response to a triggering stimulus.

What Extreme Athletes Teach Us About Sleep Deprivation

What can a 1000-mile race teach MDs about sleep? Dr Alison Kole shares sleep deprivation insights from ultramarathon racing and gives practical tips for exhausted patients.

Omalizumab May Ease Inflammation in Chronic Urticaria

In patients with antihistamine-resistant chronic spontaneous urticaria, omalizumab treatment is linked to clinical improvement and reduced systemic inflammatory markers and D-dimer levels.

Pediatric Lung Transplantation Enters a New Era

New CFTR modulators are reshaping pediatric lung transplantation, forcing clinicians to rethink when children should be referred and listed.

CVS Health's Aetna to Streamline Cancer Treatment Approvals

CVS Health's Aetna health insurance unit will cut back next year on the preapprovals it requires for treatment ⁠for cancer patients to only one medical prior authorization...

Diphtheria Debate Exposes Health Misinformation

A diphtheria death in Sicily has reignited debate over vaccines, migration, and how political spin can distort public health facts.

Azithromycin Use Cuts Cesarean Infections

Azithromycin has been shown to lower the risk for postoperative infection during cesarean deliveries when added to more standard prophylactics such as cefazolin.

Methotrexate for IBD: How Do GIs Use It?

A new study offers the most comprehensive real-world look yet at methotrexate use in treating IBD in everyday practice.

AI Digital Twins Get Better and Better: Cancer in Crosshairs

Digital twins allow doctors to simulate treatment to see what will work best — and the tech has made real strides in cardiology. Oncology remains the bigger challenge.

S1P Modulators: 5 Agents, One Safety Playbook

Five S1P modulators now span neurology and GI. Bruce Cree, MD, PhD, and others weigh in on why selectivity differences are no longer academic.

As-Needed Allergic Rhinitis Meds Comparable to Daily Use

Patients with allergic rhinitis who use medication as needed can achieve symptom control and treatment satisfaction comparable to those achieved by patients who use them daily.

Host-Directed Therapies and Phages in Lung Care

Host-directed and phage therapies are emerging as alternatives to antibiotics in managing lung infections in a worsening antimicrobial resistance crisis.

Mild Brain Injury Frequently Missed in the ED

Only 21% of adults with closed head injury have mTBI diagnosed or clinically suspected in the ED, despite 41% meeting diagnostic criteria, with missed diagnoses most common among middle-aged adults.

D10 Matches D50 for Hypoglycemia, Shows Lower Rebound Risk

A lower-concentration dextrose solution matches the standard treatment for hypoglycemia in the emergency department but carries a lower risk for rebound hypoglycemia.

A Rare Hearing Implant Bypasses Damaged Nerves

When cochlear implants failed, doctors turned to a brainstem auditory implant to restore sound awareness in a patient with profound deafness.

Two-Midnight Rule: Key Strategies for Observation Patients

The Two-Midnight Rule has created important clinical and operational strategies for hospitals.

Recommended News For You

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma

Immunotherapy and targeted radiation shrink liver tumors, enabling surgery

Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.

Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

FDA Approves New ROS1 Inhibitor for NSCLC

Recommended Articles For You

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting  

Everything You Need to Know About the Latest Hyponatremia Algorithm  

Emerging Therapies Through Immune-Engineered Blood Cell Manufacturing 

Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI Unlocks Benefits of Prostate Cancer Treatment.

2.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

3.

Investigations may result in novel combination therapies for early-stage lung cancers.

4.

Women who miss their first mammogram face higher risk of breast cancer death, study finds

5.

Venetoclax Combo Shows Promise in Younger Patients With AML

1.

Surgical Innovation Through Bone Marrow–Reserving Surgical Strategies

2.

Exercise Programming in Cancer Recovery: Evidence-Based Strategies for Clinical Practice

3.

Hematology Medication Administration Delays: Clinical Impact, Determinants, and Strategies for Improvement

4.

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis

5.

Emerging Pathways in Hematology for Modern Medicine

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II

2.

Lung Cancer: Risk Factors and Prevention

3.

Navigating the Complexities of Ph Negative ALL - Part I

4.

Navigating the Complexities of Ph Negative ALL - Part XI

5.

From Guidelines to Practice: Hematology

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot